Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IMRN 
Immuron Ltd ADR (IMRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: IMRN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.83
1 Year Target Price $4.83
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.37% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.75M USD | Price to earnings Ratio - | 1Y Target Price 4.83 |
Price to earnings Ratio - | 1Y Target Price 4.83 | ||
Volume (30-day avg) 1 | Beta 0.44 | 52 Weeks Range 1.50 - 2.48 | Updated Date 10/17/2025 |
52 Weeks Range 1.50 - 2.48 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -71.58% | Operating Margin (TTM) -85.58% |
Management Effectiveness
Return on Assets (TTM) -26.08% | Return on Equity (TTM) -50.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13256878 | Price to Sales(TTM) 2.02 |
Enterprise Value 13256878 | Price to Sales(TTM) 2.02 | ||
Enterprise Value to Revenue 2.75 | Enterprise Value to EBITDA 0.77 | Shares Outstanding 6705499 | Shares Floating 264226178 |
Shares Outstanding 6705499 | Shares Floating 264226178 | ||
Percent Insiders - | Percent Institutions 0.34 |
Upturn AI SWOT
Immuron Ltd ADR
Company Overview
History and Background
Immuron Limited (IMRN) is an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapy products for the treatment of infectious diseases. Founded in 1998, Immuron initially focused on bovine colostrum-derived antibodies. Significant milestones include the development of Travelan and Protectyn, and securing partnerships for commercialization.
Core Business Areas
- Gastrointestinal Health: Develops and commercializes products targeting gastrointestinal infections and related conditions using bovine colostrum-derived antibody technology.
- Product Development: Research and development of new immunotherapy products to address unmet needs in infectious diseases.
Leadership and Structure
The company is led by a management team with experience in biopharmaceuticals and commercialization. Its organizational structure includes departments for research and development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Travelan: Travelan is an over-the-counter (OTC) medicine that is taken before meals to reduce the risk of Travellers' Diarrhea (TD). The active ingredient is hyperimmune bovine colostrum enriched with anti-Escherichia coli (E. coli) antibodies. Competitors include Imodium, Pepto-Bismol, and other preventative measures like probiotics.
- Protectyn: Protectyn is a dietary supplement designed to reduce gut inflammation. The active ingredient is hyperimmune bovine colostrum enriched with anti-LPS antibodies. Competitors include similar gut health supplements with different active ingredients.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and significant competition. The gastrointestinal health market is growing, driven by increasing awareness of the importance of gut health and the rising prevalence of infectious diseases.
Positioning
Immuron positions itself as a leader in developing and commercializing bovine colostrum-derived immunotherapy products. Its competitive advantage lies in its proprietary technology and established partnerships.
Total Addressable Market (TAM)
The global market for traveller's diarrhea is estimated to be worth hundreds of millions of dollars annually. The dietary supplement market is in the billions. Immuron is well positioned to take market share from each.
Upturn SWOT Analysis
Strengths
- Proprietary antibody technology
- Established commercial partnerships
- Existing product portfolio
- Clinical evidence supporting product efficacy
Weaknesses
- Limited financial resources
- Dependence on bovine colostrum supply
- Relatively small market capitalization
- Limited marketing capabilities
Opportunities
- Expanding product portfolio into new indications
- Entering new geographic markets
- Securing additional partnerships
- Increasing consumer awareness of gut health
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in consumer preferences
- Adverse events related to product use
Competitors and Market Share
Key Competitors
- IMOD
- PG
- ABT
Competitive Landscape
Immuron faces competition from larger pharmaceutical and consumer health companies with greater resources and established brands. Its competitive advantage lies in its proprietary technology and focus on specific gastrointestinal health applications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are unavailable. Consult financial resources for updated information.
Future Projections: Future growth projections are unavailable. Analyst estimates should be consulted for insights.
Recent Initiatives: Recent initiatives include product development and commercialization efforts.
Summary
Immuron is a small biopharmaceutical company with proprietary antibody technology targeting gastrointestinal health. Its strengths lie in its established partnerships and clinical evidence, but it faces challenges due to limited financial resources and competition from larger companies. Expansion into new markets and product development are key to its future growth. Immuron needs to look out for competitors entering their market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and company information may be subject to change. Conduct thorough research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immuron Ltd ADR
Exchange NASDAQ | Headquaters Carlton, VIC, Australia | ||
IPO Launch date 2017-06-09 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.immuron.com.au |
Full time employees 7 | Website https://www.immuron.com.au | ||
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.